Trial Profile

A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Oct 2025 Results presented in the Hanmi Pharmaceutical Media Release.
22 Oct 2025 According to a Hanmi Pharmaceutical media release, company announced that it has presented data from this trial at the ESMO Congress 2025 held in Berlin, Germany, on October 19.
04 Jul 2025 According to a Hanmi Pharmaceutical media release, company plans to present the first-in-human phase 1 clinical data of HM97662 at the European Society for Medical Oncology (ESMO 2025) Annual Congress this October.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com